Pathos AI raises $237 million to accelerate its cancer treatments
The New York biotech Pathos AI has raised $237 million in a Series E round, for a valuation of about $3 billion. Bristol Myers Squibb lea...
Stay informed of the latest trends and our analyses on AI








